1
|
Martinez DDAES, Periquito ADFS, Roa GG, Lupi JP, Treu CM, Lupi O. Bullous pemphigoid successfully treated with dupilumab. An Bras Dermatol 2024; 99:778-780. [PMID: 38876965 PMCID: PMC11342994 DOI: 10.1016/j.abd.2023.08.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/16/2023] [Accepted: 08/02/2023] [Indexed: 06/16/2024] Open
Affiliation(s)
- Daniela de Abreu E Silva Martinez
- Department of Immunology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
| | | | - Graciela Galva Roa
- Department of Dermatology, Policlínica Geral do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - João Pedro Lupi
- Department of Medicine, Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Curt Mafra Treu
- Department of Dermatology, Policlínica Geral do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Omar Lupi
- Department of Immunology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Department of Dermatology, Policlínica Geral do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| |
Collapse
|
2
|
Wang Z, Liu X, Ni J, Qi Y, Song Z, Piao Y. Successful Treatment of Mucous Membrane Pemphigoid with Dupilumab: A Case Report. Acta Derm Venereol 2024; 104:adv40162. [PMID: 39188088 PMCID: PMC11367779 DOI: 10.2340/actadv.v104.40162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2024] [Accepted: 08/05/2024] [Indexed: 08/28/2024] Open
Abstract
Abstract is missing (Short communication)
Collapse
Affiliation(s)
- Zhiyi Wang
- First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
| | - Xiaojing Liu
- First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
| | - Jing Ni
- First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
| | - Yushuo Qi
- First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
| | - Zhiqi Song
- First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
| | - Yongjun Piao
- First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
| |
Collapse
|
3
|
Lamb J, Purdy K, Sutherland A. Use of dupilumab for recalcitrant bullous pemphigoid: A case report. SAGE Open Med Case Rep 2024; 12:2050313X241274855. [PMID: 39185064 PMCID: PMC11342423 DOI: 10.1177/2050313x241274855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2024] [Accepted: 06/17/2024] [Indexed: 08/27/2024] Open
Abstract
Bullous pemphigoid is an autoimmune blistering disease affecting the dermo-epidermal junction, most commonly seen in older patients. First-line treatment includes systemic, topical corticosteroids and/or steroid-sparing immunosuppressants. Treatment with these medications may be limited by their safety profile. Dupilumab is a humanized monoclonal antibody targeting interleukin-4 and interleukin-13 cytokines currently indicated for moderate-to-severe atopic dermatitis, severe asthma, chronic rhinosinusitis with nasal polyposis, and moderate-to-severe prurigo nodularis. We report a case of a patient with recalcitrant bullous pemphigoid effectively treated with dupilumab.
Collapse
Affiliation(s)
- Jillian Lamb
- Division of Clinical Dermatology and Cutaneous Science, Department of Medicine, Dalhousie University, Halifax, NS, Canada
| | - Kerri Purdy
- Division of Clinical Dermatology and Cutaneous Science, Department of Medicine, Dalhousie University, Halifax, NS, Canada
| | - Ashley Sutherland
- Division of Clinical Dermatology and Cutaneous Science, Department of Medicine, Dalhousie University, Halifax, NS, Canada
| |
Collapse
|
4
|
Granados-Betancort E, Sánchez-Díaz M, Muñoz-Barba D, Arias-Santiago S. Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review. J Clin Med 2024; 13:4844. [PMID: 39200987 PMCID: PMC11355228 DOI: 10.3390/jcm13164844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Revised: 07/25/2024] [Accepted: 08/01/2024] [Indexed: 09/02/2024] Open
Abstract
Background: Bullous pemphigoid (BP) is an autoimmune disease characterized by the appearance of very pruritic subepidermal blisters. It appears mostly in the elderly and is associated with multiple comorbidities, which makes its management and treatment difficult. The purpose of this systematic review is to compile current information on published cases of BP treated with omalizumab (omalizumab) and dupilumab (dupilumab) in order to obtain information on clinical efficacy and safety data available. Methods: A literature search of all cases of BP treated with omalizumab/dupilumab published in the literature up to January 2024 was performed using the Pubmed database. After an exhaustive search, a total of 61 studies encompassing 886 patients met the inclusion criteria and were included in the review. Results: The majority of patients with BP treated with omalizumab/dupilumab presented a significant improvement in symptomatology, being very safe drugs with minimal side effects. The main limitation of the presented review is the quality of the included studies, most of them being case series or individual cases. The development of studies with a higher level of scientific evidence in the near future would be of great interest. Conclusions: Both omalizumab and dupilumab appear to be effective options for treating BP in patients refractory to other pharmacological therapies. They are drugs with a good safety profile and the adverse reactions associated with their use are infrequent and generally mild.
Collapse
Affiliation(s)
| | - Manuel Sánchez-Díaz
- Skin Autoimmune Diseases Unit, Hospital Universitario Virgen de las Nieves, 18002 Granada, Spain
- Dermatology Department, Hospital Universitairo Virgen de las Nieves, Instituto de Investigación Biosanitaria IBS Granada, 18002 Granada, Spain
| | - Daniel Muñoz-Barba
- Dermatology Department, Hospital Universitairo Virgen de las Nieves, Instituto de Investigación Biosanitaria IBS Granada, 18002 Granada, Spain
| | - Salvador Arias-Santiago
- Dermatology Department, Hospital Universitairo Virgen de las Nieves, Instituto de Investigación Biosanitaria IBS Granada, 18002 Granada, Spain
- School of Medicine, Dermatology Deparment, University of Granada, 18071 Granada, Spain
| |
Collapse
|
5
|
Verma KK, Matthew E, Deligonul FZ, Blegen K, Tarbox M. The Diagnostic Challenge of a Dyshidrosiform Bullous Pemphigoid: A Palmar Puzzle. Cureus 2024; 16:e66470. [PMID: 39246960 PMCID: PMC11380570 DOI: 10.7759/cureus.66470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/08/2024] [Indexed: 09/10/2024] Open
Abstract
We present a unique case of an 89-year-old male with Alzheimer's disease who developed hemorrhagic blisters on his palms, which ruptured with time and were followed by pruritic erythematous lesions across his chest, upper back, lower abdomen, and thighs. The patient was diagnosed with dyshidrosiform bullous pemphigoid (DBP), an uncommon variant of the autoimmune condition bullous pemphigoid characterized by cutaneous and mucosal blistering, which commonly appears as vesiculobullous eruptions in the palmoplantar areas and may spread to other parts of the body. Less than 100 cases of DBP have been documented in the medical literature. Since DBP is difficult to identify and treat due to its clinical appearance similar to pompholyx, we reviewed the treatment of DBP and included clinical images and direct immunofluorescence (DIF) staining technique images to better establish the diagnosis.
Collapse
Affiliation(s)
- Kritin K Verma
- Medicine, Texas Tech University Health Sciences Center, Lubbock, USA
| | - Ethan Matthew
- Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA
| | - Fatma Z Deligonul
- Osteopathic Medicine, University of the Incarnate Word, San Antonio, USA
| | - Kristina Blegen
- Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA
| | - Michelle Tarbox
- Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA
| |
Collapse
|
6
|
Thevan J, Schmauch E, Nilsson J, Guillet CF, Boesch A, Krähenbühl L, Meier-Schiesser B, Schmid-Grendelmeier P, Kündig T, Kolios AGA. Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study. Dermatology 2024:1-8. [PMID: 39074468 DOI: 10.1159/000540590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Accepted: 07/23/2024] [Indexed: 07/31/2024] Open
Abstract
INTRODUCTION Dupilumab has emerged as a promising treatment option for bullous pemphigoid (BP). Rapid identification of responders could avoid the need for additional immunosuppressive treatments that are associated with increased morbidity and mortality. METHODS To investigate the course of itch as an early indicator of treatment response, data of 12 BP patients treated with dupilumab at the University Hospital of Zurich were retrospectively evaluated. Disease severity was assessed by bullous pemphigoid disease area index (BPDAI) and pruritus by a numeric rating scale (NRS, 0-10) at baseline; days 1, 3, 14; months 1, 2; and the last follow-up. RESULTS A total of 8/12 patients (67%) had complete response, and 4/12 patients (33%) had partial response during dupilumab treatment. Notably, a highly significant reduction of pruritus (p < 0.0001) was observed already on day 1 with further improvement at later time points. Moreover, fast relief of itch could predict treatment response with a significant correlation to clinical response on day 14 (Spearman correlation R 0.70, p value 0.025), with a positive but non-significant trend on day 3 (R 0.63, p value 0.091). Additionally, 92% (11/12 patients) were on dupilumab monotherapy at the last follow-up without any concomitant systemic or topical treatment for BP. CONCLUSIONS The rapid and significant decline in BP-associated pruritus observed with dupilumab correlated significantly with disease remission. Early evaluation of pruritus response could change how BP is treated in the future and avoid additional immunosuppressive treatment in BP.
Collapse
Affiliation(s)
- Jeivicaa Thevan
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland,
| | - Eloi Schmauch
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
- A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland
- Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - Jakob Nilsson
- Department of Immunology, University Hospital Zurich, Zurich, Switzerland
| | | | - Andrea Boesch
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - Lukas Krähenbühl
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | | | - Peter Schmid-Grendelmeier
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - Thomas Kündig
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - Antonios G A Kolios
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Zurich, Switzerland
- Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
7
|
Hansen I, Gebhardt C, Booken N, Schneider SW. Erfolgreiche Behandlung eines Checkpoint‐Inhibitor‐assoziierten bullösen Pemphigoids mit Dupilumab bei Angiosarkom. J Dtsch Dermatol Ges 2024; 22:587-590. [PMID: 38574016 DOI: 10.1111/ddg.15340_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 11/16/2023] [Indexed: 04/06/2024]
Affiliation(s)
- Inga Hansen
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Christoffer Gebhardt
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Nina Booken
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Stefan W Schneider
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| |
Collapse
|
8
|
Hansen I, Gebhardt C, Booken N, Schneider SW. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma. J Dtsch Dermatol Ges 2024; 22:587-589. [PMID: 38379256 DOI: 10.1111/ddg.15340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 11/16/2023] [Indexed: 02/22/2024]
Affiliation(s)
- Inga Hansen
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Christoffer Gebhardt
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Nina Booken
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - Stefan W Schneider
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| |
Collapse
|
9
|
Hu L, Huang R, Jiang F, You S, Wu Q. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study. Immun Inflamm Dis 2023; 11:e924. [PMID: 37506153 PMCID: PMC10367446 DOI: 10.1002/iid3.924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 05/05/2023] [Accepted: 06/15/2023] [Indexed: 07/30/2023] Open
Abstract
OBJECTIVE To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid. METHODS From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes. RESULTS The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0-3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment. CONCLUSION Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.
Collapse
Affiliation(s)
- Lingyu Hu
- Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
| | - Ruiting Huang
- Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
| | - Fuqiong Jiang
- Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
| | - Shuqiong You
- Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
| | - Qian Wu
- Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
| |
Collapse
|
10
|
Savoldy MA, Tadicherla T, Moureiden Z, Ayoubi N, Baldwin BT. The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab. Cureus 2022; 14:e30541. [DOI: 10.7759/cureus.30541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/21/2022] [Indexed: 11/05/2022] Open
|